Results 241 to 250 of about 58,241 (294)
Karl Rankl: Frühlingslied: Autograph, Klavierauszug ; Berlin ; 1933 ; [3 Bl.]
, 1933 Erdinger, Maria
core
Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential. [PDF]
Front ImmunolZheng CM +5 more
europepmc +1 more source
The effects of SARS-CoV-2 on bone homeostasis. [PDF]
Front Endocrinol (Lausanne)Delpino MV, Quarleri J.
europepmc +1 more source
Evaluation of Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Biomarker Concentrations in the Saliva of Patients with Periodontitis and Depression. [PDF]
Clin Exp Dent ResEsmaeilnejad A +3 more
europepmc +1 more source
Periodontal disease and endocrine imbalance: a molecular pathways perspective. [PDF]
Front Dent MedMartínez-García M, Hernández-Lemus E.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bone, 2022
Since the receptor activator of nuclear factor-kappa B ligand (RANKL), its cognate receptor activator of nuclear factor-kappa B (RANK), and the decoy receptor osteoprotegerin (OPG) were discovered, a number of studies have uncovered the crucial role of the RANKL-RANK-OPG pathway in controlling the key aspect of bone homeostasis, the immune system ...
Noriko, Takegahara +2 more
openaire +2 more sources
Since the receptor activator of nuclear factor-kappa B ligand (RANKL), its cognate receptor activator of nuclear factor-kappa B (RANK), and the decoy receptor osteoprotegerin (OPG) were discovered, a number of studies have uncovered the crucial role of the RANKL-RANK-OPG pathway in controlling the key aspect of bone homeostasis, the immune system ...
Noriko, Takegahara +2 more
openaire +2 more sources
Folia Pharmacologica Japonica, 2023
Periodontal disease is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone. It is one of the most common infectious diseases in humans, being the leading cause of tooth loss in adults. Recently, it has been shown that the receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and ...
Yutaro, Ando, Masayuki, Tsukasaki
openaire +2 more sources
Periodontal disease is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone. It is one of the most common infectious diseases in humans, being the leading cause of tooth loss in adults. Recently, it has been shown that the receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and ...
Yutaro, Ando, Masayuki, Tsukasaki
openaire +2 more sources
RANKL and osteoimmunology in periodontitis
Journal of Bone and Mineral Metabolism, 2020Periodontitis, one of the most common infectious diseases in humans, is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone, which ultimately leads to tooth loss. Recently, it was revealed that the osteoclastic bone damage that occurs during periodontitis is dependent on the receptor activator of NF ...
openaire +2 more sources
Journal of Molecular Medicine, 2011
Receptor-activator of NF-κB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE, and ODF) and its tumor necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer.
Hanada +7 more
openaire +2 more sources
Receptor-activator of NF-κB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE, and ODF) and its tumor necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer.
Hanada +7 more
openaire +2 more sources
The RANKL Pathway and Denosumab
Rheumatic Disease Clinics of North America, 2011Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk ...
openaire +2 more sources